Merck (MSD) Clinical Trials

Clinical trials sponsored by Merck (MSD) — phases, conditions and reported results. Data from ClinicalTrials.gov.

• Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
  Phase 2 · Cancer of Head and Neck · Completed · May 11, 2023
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Adva
  Phase 3 · Head and Neck Neoplasms · Active, not recruiting · Aug 20, 2025
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chem
  Phase 3 · Platinum Sensitive · Active, not recruiting · Feb 7, 2018
• Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Ther
  Phase 3 · Non-small Cell Lung Cancer · Active, not recruiting · Sep 19, 2024
• Efficacy of Suvorexant on Post-operative Sleep Disturbance
  Phase 4 · Postoperative Insomnia · Completed · Jul 23, 2026
• Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic
  Phase 2 · Microsatellite Stable Metastatic Colorectal Cancer · Terminated · Jul 22, 2026
• Pembrolizumab In Central Nervous System Metastases
  Phase 2 · Brain Metastases · Active, not recruiting · Jun 26, 2026
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participan
  Phase 3 · Metastatic Esophageal Squamous Cell Carcinoma · Completed · Jul 20, 2026
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small
  Phase 2 · Non-Small Cell Lung Cancer Metastatic · Active, not recruiting · Apr 2, 2024
• A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/
  Phase 2 · Sarcoma · Active, not recruiting · Oct 29, 2025
• Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
  Phase 2 · Squamous Cell Carcinoma · Active, not recruiting · May 29, 2025
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK
  Phase 1 · Advanced or Metastatic Solid Tumors · Completed · Jul 15, 2026
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast C
  Phase 3 · Breast Cancer · Active, not recruiting · Dec 8, 2021
• A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
  Phase 2 · Non-segmental Vitiligo · Terminated · Mar 17, 2026
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metas
  Phase 3 · Prostatic Neoplasms · Completed · Dec 20, 2023

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials